HIV-1 Virologic Suppression With TMB-365 and TMB-380 Antibodies Study

This study is testing two antibody-based treatments (TMB-365 and TMB-380) as a replacement for daily HIV pills in people living with HIV-1 whose viral load is already well controlled on their current medications. **You may be eligible if...** - You are 18 or older and have HIV-1 - You have been on continuous HIV treatment for at least 6 months with an undetectable viral load (under 50 copies/mL) - Your CD4+ T cell count is at least 350 cells/mm³ - Your blood counts, liver, and kidney function are within acceptable ranges - You are willing to use contraception if applicable **You may NOT be eligible if...** - You have previously received monoclonal antibody treatment for HIV - You are currently receiving injectable HIV treatment (cabotegravir/rilpivirine) - You have a history of virologic failure on two or more HIV treatment regimens - You are pregnant, planning a pregnancy, or breastfeeding - You have hepatitis B or C infection, or a serious ongoing illness - You have a history of severe allergic reactions to monoclonal antibodies or vaccines Talk to your doctor to see if this trial is right for you.